| Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
pharmaceutical_companies:pfizer [2022/09/29 19:33] pamela [Allegations of Funding Terrorism] | pharmaceutical_companies:pfizer [2023/01/10 17:37] (current) liam [Payments to Individuals] |
|---|
| | [[:Dawn Bowdish]] | Research Award | Unknown | Funds for pneumonia research from [[:Ontario Lung Association]] and [[Pfizer]], and ASPIRE-Pfizer New Investigator Award.((Bowdish, D. M. E. (2013, February 11). //Dr. Dawn Bowdish receives a research award from the Ontario Lung Association and Pfizer Canada (and gets to attend a swanky event to receive it!).// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/AQqx1)) ((Bowdish, D. M. E. (2011, July 3). //Dawn wins ASPIRE-Pfizer New Investigator Award.// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/Dvre1)) | | | [[:Dawn Bowdish]] | Research Award | Unknown | Funds for pneumonia research from [[:Ontario Lung Association]] and [[Pfizer]], and ASPIRE-Pfizer New Investigator Award.((Bowdish, D. M. E. (2013, February 11). //Dr. Dawn Bowdish receives a research award from the Ontario Lung Association and Pfizer Canada (and gets to attend a swanky event to receive it!).// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/AQqx1)) ((Bowdish, D. M. E. (2011, July 3). //Dawn wins ASPIRE-Pfizer New Investigator Award.// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/Dvre1)) | |
| | [[:Richard Choi]] | Speakers Bureau/Honoraria/Consulting | Unknown | Disclosed during CardioVascUpdate presentation.((Verma, S., Bucci, C., Choi, R., & Gupta, A. (2020, June 12). //Navigating Vascular Protective Strategies in HighRisk Patients During the Current Era: Practical Applications.// CardioVascUpdate. https://web.archive.org/web/20210304170904/https://cardiovascupdate.ca/files/2020/CV%20Update%20Symposium-Presentation.pdf)) | | | [[:Richard Choi]] | Speakers Bureau/Honoraria/Consulting | Unknown | Disclosed during CardioVascUpdate presentation.((Verma, S., Bucci, C., Choi, R., & Gupta, A. (2020, June 12). //Navigating Vascular Protective Strategies in HighRisk Patients During the Current Era: Practical Applications.// CardioVascUpdate. https://web.archive.org/web/20210304170904/https://cardiovascupdate.ca/files/2020/CV%20Update%20Symposium-Presentation.pdf)) | |
| | | [[:Nigel Crawford]] | Research | Unknown | "Investigator on a number of epidemiological surveillance research and vaccine safety research. Funds received by employer", [[:Murdoch Children's Research Institute]] (MCRI).((//Australian Technical Advisory Group on Immunisation - Conflict of Interest.// Australia Government Department of Health and Aged Care. Retrieved October 24, 2022, from https://web.archive.org/web/20221024032912/https://www.health.gov.au/sites/default/files/atagi-conflict-of-interest-disclosures.pdf)) | |
| | [[:David Fisman]] | Honorarium | Unknown | Honorarium paid for advisory board meetings regarding COVID-19 related projects.((Fisman, D. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2020/10/Declaration-of-Interest_Science-Table_David-Fisman2.pdf)) | | | [[:David Fisman]] | Honorarium | Unknown | Honorarium paid for advisory board meetings regarding COVID-19 related projects.((Fisman, D. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2020/10/Declaration-of-Interest_Science-Table_David-Fisman2.pdf)) | |
| | [[:Soren Gantt]] | Grant | Unknown | Research grant paid to Gantt.((Lebatteux, D., Soudeyns, H., Boucoiran, I., Gantt, S., & Diallo, A. B. (2022). //Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures.// bioRxiv. Preprint. https://doi.org/10.1101/2022.02.07.479343)) | | | [[:Soren Gantt]] | Grant | Unknown | Research grant paid to Gantt.((Lebatteux, D., Soudeyns, H., Boucoiran, I., Gantt, S., & Diallo, A. B. (2022). //Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures.// bioRxiv. Preprint. https://doi.org/10.1101/2022.02.07.479343)) | |
| UCSF Becomes First Partner in Both Small-Molecule and Biologics Discovery | UCSF Becomes First Partner in Both Small-Molecule and Biologics Discovery |
| |
| By Kristen Bole | By Kristen Bole {{ :pharmaceutical_companies:pfizer_2013_ucsf.png?400|}} |
| |
| Pfizer has announced the expansion of its [[:Centers for Therapeutic Innovation]] (CTI) into the development of small-molecule drug candidates through a partnership with UC San Francisco. | Pfizer has announced the expansion of its [[:Centers for Therapeutic Innovation]] (CTI) into the development of small-molecule drug candidates through a partnership with UC San Francisco. |
| |
| The collaboration builds upon an October 2010 agreement between CTI and UCSF in large-molecule – also called biologics – discovery, with both agreements aiming to accelerate the translation of biomedical research into new medications and therapies. ((https://web.archive.org/web/20210630074451/https://www.ucsf.edu/news/2013/05/106276/pfizers-centers-therapeutic-innovation-partners-ucsf-expand-drug-discovery)) | The collaboration builds upon an October 2010 agreement between CTI and UCSF in large-molecule – also called biologics – discovery, with both agreements aiming to accelerate the translation of biomedical research into new medications and therapies. ((https://web.archive.org/web/20210630074451/https://www.ucsf.edu/news/2013/05/106276/pfizers-centers-therapeutic-innovation-partners-ucsf-expand-drug-discovery)) |
| | |
| | ==== Pfizer Recommends Hydroxychloroquine for Covid-19 ==== |
| | {{ :pharmaceutical_companies:pfizer_hcq_treats_covid_-_mechanism_page.png?600|}} |
| | See Ashmedai article at Substack or [[:Hydroxychloroquine]] in wiki. ((https://ashmedai.substack.com/p/pfizer-still-recommends-hydroxychloroquine)) |
| | |
| | TO give some added perspective, the FDA’s evidence that HCQ does NOT work is EXCLUSIVELY regarding hospitalized covid patients - precisely the same folks for which Pfizer is recommending HCQ!! |
| | |
| | Pfizer is so transcendently theophanic that its pronouncements are the embodiment of the scientific method, as we all witnessed when the CDC Director herself understood that a CNN report of Pfizer’s proclamation of its vaccine trial’s results amounted to an official communique of eternally settled Scientific fact. |
| | {{ :pharmaceutical_companies:pfizer_hcq_treats_covid_text_box_large.png?400|}} |
| | |
| | |
| | If Pfizer declares that HCQ works to treat covid - we can limit their revised catechism to late stage severe covid if you really want to be nitpicky here - then doesn’t this mean that the formerly heretical position that HCQ can treat covid is now fundamental doctrinal truth?? |
| | |
| | Alternatively, if we can’t trust Pfizer, the oracle of science, who can we trust???? |
| | |
| | Pfizer pdf Wayback((https://web.archive.org/web/20221213102408/https://pfizermedical.pfizerpro.com/api/vc/en/medical/assets/343db662-0565-4062-8956-00ddd5bb4fbb/COVID-19%20Antiviral%20-%202.%20Clinical%20Presentation-Proactive.pdf)) |